Oxford Biomedica plc, the leading gene and cell therapy group is to collaborate with PhoreMost Limited, the Cambridge-based biopharmaceutical company, to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed.
PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, to identify therapeutic candidates for Oxford Biomedica’s LentiVector gene therapy delivery system. The programme will initially focus on CAR-T therapy and aims to develop next-generation cell therapies with significantly improved efficacy and durability.
Dr Chris Torrance, CEO, PhoreMost, said: “This collaboration with Oxford Biomedica, a global pioneer in cell and gene therapies, is further recognition of the power of SITESEEKER, offering an exciting opportunity to discover and accelerate the development of clinical stage products. The natural complementarity between SITESEEKER and LentiVector offers great promise for this and future collaborations between the two companies.”
John Dawson, CEO of Oxford Biomedica, said: “We are excited to apply this next-generation technology to our LentiVector® platform. The collaboration has the potential to deliver more effective CAR-T therapies, and we look forward to working closely with the PhoreMost team.”
Bath-based Future plc, the publisher of specialist online and print magazines, said trading in its…
The university of Bristol was one of six organisations to receive a contract from the…
Oxford BioDynamics Plc is teaming up with researchers at King's College London in a bid…
More than a quarter of a million extra construction workers are needed in the UK…
Kent-based housebuilder Vistry revealed it was on track to deliver more than 10% growth in…
A Dorset-based company, which has developed ground-breaking technology to recycle plastic waste and turn it…